BioXcel Therapeutics Files 8-K
Ticker: BTAI · Form: 8-K · Filed: Jul 16, 2024 · CIK: 1720893
Sentiment: neutral
Topics: financial-reporting, sec-filing
TL;DR
BioXcel filed an 8-K on July 16th for financial updates.
AI Summary
BioXcel Therapeutics, Inc. filed an 8-K on July 16, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This filing serves as an official update from BioXcel Therapeutics to the SEC regarding its financial condition and operations, which is important for investors to monitor company performance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure and does not contain information that inherently increases risk.
Key Players & Entities
- BioXcel Therapeutics, Inc. (company) — Registrant
- July 16, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-38410 (identifier) — Commission File Number
- 555 Long Wharf Drive New Haven, CT 06511 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing by BioXcel Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on BioXcel Therapeutics, Inc.'s results of operations and financial condition, and to file financial statements and exhibits.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on July 16, 2024.
What is the state of incorporation for BioXcel Therapeutics, Inc.?
BioXcel Therapeutics, Inc. is incorporated in Delaware.
What is the Commission File Number for BioXcel Therapeutics, Inc.?
The Commission File Number for BioXcel Therapeutics, Inc. is 001-38410.
Where are BioXcel Therapeutics, Inc.'s principal executive offices located?
BioXcel Therapeutics, Inc.'s principal executive offices are located at 555 Long Wharf Drive, New Haven, CT 06511.
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-07-16 07:00:27
Key Financial Figures
- $0.001 B — ch registered Common Stock, par value $0.001 BTAI The Nasdaq Capital Market Indic
Filing Documents
- tm2419377d1_8k.htm (8-K) — 26KB
- tm2419377d1_ex99-1.htm (EX-99.1) — 34KB
- 0001104659-24-080022.txt ( ) — 238KB
- btai-20240716.xsd (EX-101.SCH) — 3KB
- btai-20240716_lab.xml (EX-101.LAB) — 33KB
- btai-20240716_pre.xml (EX-101.PRE) — 22KB
- tm2419377d1_8k_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. Although it has not finalized its full financial results for the quarterly period ended June 30, 2024, on July 16, 2024, BioXcel Therapeutics, Inc. (the "Company") issued a press release reporting certain unaudited preliminary financial results for the three months ended June 30, 2024. A copy of the Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d)Exhibits. Exhibit No. Description 99.1 Press release, dated July 16, 2024 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 16, 2024 BIOXCEL THERAPEUTICS, INC. /s/ Richard Steinhart By: Richard Steinhart Title: Chief Financial Officer